Core Viewpoint - Ocugen, Inc. has successfully closed an underwritten registered direct offering of 15 million shares at $1.50 per share, resulting in net proceeds of $20.85 million, aimed at supporting its operations and extending its cash runway into Q4 2026 [1][2]. Group 1: Offering Details - The offering consisted of 15,000,000 shares priced at $1.50 each, leading to net proceeds of $20.85 million after expenses [1]. - The financing was led by RTW Investments, with participation from both new and existing investors [1]. - Oppenheimer & Co. served as the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds will be allocated for general corporate purposes, capital expenditures, working capital, and administrative expenses [2]. - The funding is expected to extend the company's cash runway into the fourth quarter of 2026 [2]. Group 3: Company Overview - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, utilizing a modifier gene therapy platform to address complex diseases caused by multiple gene network imbalances [5]. - The company is developing programs for inherited retinal diseases and blindness conditions affecting millions globally, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [5].

Ocugen Inc (NASDAQ:OCGN) shares sank sharply on Wednesday after the biotech company announced a $22.5 million underwritten offering of common stock. Here’s what investors need to know. • Ocugen is trading in a tight range. What’s the outlook for OCGN shares?Dilution Fears Pressure OCGN StockThe company is issuing 15 million new shares at $1.50 apiece, with all shares sold by Ocugen itself, and plans to use the proceeds for general corporate purposes, capital spending and working capital.Equity offerings oft ...

Core Viewpoint - Ocugen, Inc. has announced the pricing of an underwritten offering of 15 million shares of common stock at $1.50 per share, aiming for gross proceeds of $22.5 million, expected to close around January 22, 2026 [1]. Group 1: Offering Details - The offering consists of 15,000,000 shares priced at $1.50 each, resulting in gross proceeds of $22.5 million before expenses [1]. - The offering is led by RTW Investments, with participation from both new and existing investors [1]. - Oppenheimer & Co. is the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, capital expenditures, working capital, and general and administrative expenses [2]. Group 3: Company Overview - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, with a modifier gene therapy platform aimed at addressing significant unmet medical needs [5]. - The company is developing programs for inherited retinal diseases and blindness diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [5].

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights such as buy and sell ratings, product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-by-market analysis for major pharmaceutical companies [1]

PresentationOperator Good morning, and welcome to Ocugen's webcast to discuss data from the first half of patients completing 1 year since treatment in the OCU410 Phase II ArMaDa clinical trial for geographic atrophy. Please note that this call is being recorded at this time. [Operator Instructions] Joining on today's webcast are Dr. Shankar Musunuri, Chairman, CEO and Co-Founder; Dr. Huma Qamar, Chief Medical Officer; and Dr. Arun Upadhyay, Chief Scientific Officer, along with distinguished clinical trial ...

Ocugen, Inc. (NASDAQ:OCGN) on Thursday shared preliminary data from its phase 2 clinical trial for OCU410, a gene therapy targeting geographic atrophy. • Ocugen stock is taking a hit today. What’s weighing on OCGN shares?The stock’s decline comes as the broader market is experiencing gains, with major indices such as the S&P 500 up 0.64% and the Nasdaq gaining 1.07%.Ocugen’s Phase 2 Trial Shows 46% Lesion ReductionPreliminary results from the Phase 2 ArMaDa clinical trial indicate a 46% reduction in lesion ...

Ocugen (NasdaqCM:OCGN) Update / briefing January 15, 2026 08:30 AM ET Company ParticipantsSwayampakula Ramakanth - Managing DirectorLejla Vajzovic - Clinical Trial InvestigatorJay Chablani - Clinical Trial InvestigatorHuma Qamar - CMOArun Upadhyay - Chief Scientific OfficerElemer Piros - Managing DirectorArshad Khanani - Clinical Trial InvestigatorShankar Musunuri - Chairman, CEO, and Co-FounderConference Call ParticipantsRobert LeBoyer - Senior Biotechnology AnalystMichael Okunewitch - Senior Biotechnology ...

Core Insights - Ocugen, Inc. announced positive preliminary 12-month data from the Phase 2 ArMaDa clinical trial for OCU410, a gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD) [1][4] - The global prevalence of dAMD is 266 million, with GA affecting approximately 2-3 million people in the U.S. and Europe [1][8] Clinical Trial Findings - Phase 2 results show a 46% reduction in lesion growth compared to control, with a 50% responder rate achieving over 50% lesion size reduction [5][6] - No serious adverse events related to OCU410 were reported in both Phase 1 and Phase 2 trials [2][5] - The medium dose achieved a 54% lesion reduction, while the high dose achieved a 36% reduction compared to control [6] Treatment Landscape - Current treatment options for dAMD in the U.S. are limited and involve frequent injections with side effects, leaving approximately 2 million patients in Europe without approved treatments [2][8] - OCU410 is a multifunctional gene therapy targeting multiple pathways associated with GA, contrasting with existing therapies that target a single mechanism [3][9] Future Developments - Ocugen plans to file a Biologics License Application (BLA) for OCU410 in 2028, aiming for three regulatory submissions for marketing authorization within three years [7][10] - Full data from the Phase 2 clinical trial is expected to be reported later this quarter, with Phase 3 trials anticipated to begin in 2026 [4][7]

Core Insights - Ocugen, Inc. is hosting a conference call and live webcast to discuss data from the OCU410 Phase 2 ArMaDa clinical trial, focusing on patients who have completed one year since treatment [1] - The conference call is scheduled for January 15, 2026, at 8:30 a.m. ET, featuring key opinion leaders and Ocugen's executive leadership [1][2] Company Overview - Ocugen, Inc. is a biotechnology leader specializing in gene therapies for blindness diseases, utilizing a modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [3] - The company is developing therapies for inherited retinal diseases and blindness diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, which affect millions globally [3]

Core Insights - Ocugen, Inc. announced positive Phase 1 GARDian1 trial results for OCU410ST, a novel modifier gene therapy for Stargardt disease, published in the peer-reviewed journal Nature Eye [1][2] Group 1: Clinical Trial Results - The Phase 1 GARDian1 trial demonstrated robust efficacy and safety outcomes, indicating a favorable safety and tolerability profile for OCU410ST [3][4] - Among six patients with gradable Fundus Auto Fluorescence images, atrophic lesion growth was reduced by 54% in treated eyes compared to untreated eyes over 12 months [5] - Treated eyes showed a 50% slower lesion expansion rate compared to untreated eyes, below published natural history rates [5] - Visual acuity improved in treated eyes, with a gain of +6 letters in Best Corrected Visual Acuity (BCVA) compared to a decline in untreated eyes [5] - No drug-related serious adverse events were reported during the trial [5] Group 2: Disease Background - Stargardt disease is the most common form of inherited macular degeneration, affecting over 100,000 individuals in the U.S. and Europe, characterized by progressive central vision loss [3][7] - Currently, there are no FDA-approved treatments for Stargardt disease, highlighting a critical unmet medical need [3][7] Group 3: Future Developments - The ongoing Phase 2/3 GARDian3 trial is progressing ahead of schedule, with anticipated enrollment completion in the first quarter of 2026 [4] - The company plans to file a Biologics License Application (BLA) in the first half of 2027, aiming for three regulatory submissions within three years [4] Group 4: Technology Overview - OCU410ST utilizes an AAV5 delivery platform to deliver the RORA gene to the retina, addressing multiple pathophysiological pathways linked to Stargardt disease [6] - The therapy aims to provide a gene-agnostic modification strategy that could benefit patients regardless of their underlying ABCA4 mutation [4][6] Group 5: Company Overview - Ocugen, Inc. focuses on discovering and developing novel gene therapies for blindness diseases, aiming to address significant unmet medical needs through innovative approaches [8]